



Date: 12.08.2026

To
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Dear Sir / Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Subject: Outcome of Board Meeting held on August 12, 2026

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**Listing Regulations**”), we hereby inform that the Board of Directors of Pharmaids Pharmaceuticals Limited (“**Company**”) in their Meeting held today i.e., Wednesday, August 12, 2026, have, inter alia considered and approved:

1. The Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026 (‘Financial Results’).

A copy of the Financial Results along with Limited Review Report issued by the Statutory Auditors of the Company, M/s PPKG & Co, Chartered Accountants, is enclosed herewith.

The advertisement will also be published in the newspaper, in accordance with the Listing Regulations, containing a Quick Response (QR) Code and details of the webpage where the complete financial results of the Company, along with the Limited Review Report, will be available.

2. Notice of 37th Annual General Meeting (AGM) of the Company to be held through Video Conferencing (VC) or Other Audio-Visual Means (OAVM) in accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India (SEBI) and other AGM related matters.

The Notice of the Annual General Meeting will be shared in due course.

The Board Meeting commenced at 04:57 P.M. and concluded at 06:15 P.M.

Kindly take the same on your record and oblige.

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)

Independent Auditor's Review Report on unaudited quarterly standalone financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors of
Pharmaids Pharmaceuticals Limited

We have reviewed the accompanying statement of Unaudited Standalone Financial Results of Pharmaids Pharmaceuticals Limited for the Quarter ended 30th June 2026 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in

which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For PPKG & Co.
Chartered Accountants
(Firm's Registration No. 009655S)


Girdhari Lal Toshniwal
(Partner)
(Membership No. 205140)
UDIN: 26205140PSRVAR3555'



Place: Hyderabad
Date: 12th August 2026

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979


Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Standalone Financial Results for the Quarter ended 30th June, 2026

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended Jun 30, 2026 (Unaudited)	Quarter ended Jun 30, 2025 (Unaudited)	Quarter ended Mar 31, 2026 (Audited)	Year ended Mar 31, 2026 (Audited)
Income				
Revenue from operations	-	111.53	268.89	1,060.25
Other income	4.59	34.72	6.16	66.04
Total income	4.59	146.25	275.05	1,126.29
Expenses				
Cost of materials consumed	-	5.94	71.65	1,091.05
Purchase of stock-in-trade	-	54.72	-	39.60
Changes in inventories of finished goods and work-in-progress	-	45.71	191.82	11.50
Employee benefits expense	69.26	139.74	85.24	539.54
Finance costs	57.30	111.06	59.96	330.15
Depreciation and amortisation expense	5.68	5.10	5.27	21.38
Other expenses	17.64	353.13	28.14	799.45
Total expenses	149.89	715.41	442.08	2,832.67
Profit/ (Loss) before exceptional items and tax	(145.30)	(569.17)	(167.04)	(1,706.38)
Exceptional items	420.00	0.03	(2.04)	311.04
Profit/ (Loss) before tax	274.70	(569.13)	(169.08)	(1,395.34)
Tax expense				
Current tax	-	-	-	-
Deferred tax	61.21	(132.83)	(37.87)	(351.62)
Total Tax Expense	61.21	(132.83)	(37.87)	(351.62)
Profit/ (Loss) for the year	213.49	(436.30)	(131.21)	(1,043.72)
Other comprehensive income				
(i) Items that will not be reclassified subsequently to profit or loss				
Re-measurement on defined benefit plans and equity instruments	0.97	0.24	3.18	3.90
Income tax effect	(0.25)	(0.06)	(0.83)	(1.01)
(ii) Items that will be reclassified subsequently to profit or loss				
Effective portion of gains/(losses) on hedging instrument in cash flow hedges	-	-	-	-
Income tax effect	-	-	-	-
Other comprehensive income for the year, net of taxes	0.72	0.18	2.36	2.88
Total comprehensive income for the year	214.21	(436.12)	(128.85)	(1,040.84)
Paid-up Equity share capital (Face value Rs. 10/- per share)	3,526.78	3,526.78	3,526.78	3,526.78
Other Equity (excluding revaluation reserve)				1,811.26
Earnings per equity share				
Basic (in Rs)	0.61	(1.24)	(0.37)	(2.95)
Diluted (in Rs)	0.61	(1.24)	(0.37)	(2.95)



Independent Auditor's Review Report on unaudited quarterly consolidated financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
Pharmaids Pharmaceuticals Limited (Holding Company)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Pharmaids Pharmaceuticals Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its subsidiaries for the quarter ended 30th June 2026 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the following entities:
 - i. Adita Bio Sys Private Limited- Subsidiary Company
 - ii. Spring Labs (Partnership firm)- Stepdown Subsidiary
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of two subsidiaries included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total revenues of Rs. 412.13 Lakhs, total net(loss) after tax of Rs. (26.39) Lakhs and

total comprehensive loss of Rs (25.84) Lakhs for the quarter ended 30th June 2026, as considered in the consolidated unaudited financial results.

These interim financial statements / financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Consolidated Financial Statement is not modified in respect of the above matters.

For PPKG & Co.
Chartered Accountants
(Firm's Registration No. 009655S)


Girdhari Lal Toshniwal
(Partner)
(Membership No. 205140)
UDIN: 26205140X5IRSU1027



Place: Hyderabad
Date: 12th August 2026

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Consolidated Financial Results for the Quarter ended 30th June, 2026

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended Jun 30, 2026 (Unaudited)	Quarter ended Jun 30, 2025 (Unaudited)	Quarter ended Mar 31, 2026 (Audited)	Year ended Mar 31, 2026 (Audited)
Income				
Revenue from operations	412.14	666.36	718.38	2,788.24
Other income	4.83	4.01	9.92	28.88
Total income	416.97	670.37	728.30	2,817.12
Expenses				
Cost of materials consumed	98.66	191.85	139.82	1,474.07
Purchase of stock-in-trade	53.00	123.19	47.10	243.12
Changes in inventories of finished goods and work-in-progress	10.05	35.53	187.93	(1.93)
Employee benefits expense	246.61	418.76	272.61	1,337.74
Finance costs	60.37	119.55	64.95	349.15
Depreciation and amortisation expense	48.57	60.62	47.72	202.69
Other expenses	78.26	438.00	104.83	1,089.03
Total expenses	595.52	1,387.49	864.96	4,693.86
Profit/ (Loss) before exceptional items and tax	(178.55)	(717.12)	(136.65)	(1,876.74)
Exceptional items	420.00	0.03	(8.94)	246.46
Profit/ (Loss) before tax	241.45	(717.08)	(145.60)	(1,630.28)
Tax expense				
Current tax	-	-	-	-
Tax paid for earlier years	-	-	-	-
Deferred tax	54.30	(185.55)	(37.10)	(473.09)
Total Tax Expense	54.30	(185.55)	(37.10)	(473.09)
Profit/ (Loss) for the year	187.15	(531.53)	(108.49)	(1,157.19)
Other comprehensive income				
(i) Items that will not be reclassified subsequently to profit or loss				
Re-measurement on defined benefit plans and equity instruments	1.73	1.11	0.66	6.94
Income tax effect	(0.46)	(0.21)	(0.30)	(1.85)
(ii) Items that will be reclassified subsequently to profit or loss				
Effective portion of gains/(losses) on hedging instrument in cash flow hedges	-	-	-	-
Income tax effect	-	-	-	-
Other comprehensive income for the year, net of taxes	1.27	0.90	0.36	5.08
Total comprehensive income for the year	188.42	(530.64)	(108.13)	(1,152.11)
Profit/ (Loss) attributable to:				
Equity holders of the Holding company	220.53	(495.14)	(180.90)	(1,171.69)
Non-controlling interest	(33.38)	(36.39)	72.41	14.51
Profit/ (Loss) for the year	187.15	(531.53)	(108.49)	(1,157.19)
Other comprehensive income attributable to:				
Equity holders of the Holding company	1.25	(0.84)	0.30	5.01
Non-controlling interest	0.02	1.74	0.06	0.07
Other comprehensive income for the year	1.27	0.90	0.36	5.08
Total comprehensive income attributable to:				
Equity holders of the Holding company	221.78	(495.99)	(180.60)	(1,166.68)
Non-controlling interest	(33.36)	(34.65)	72.47	14.58
Total comprehensive income for the year	188.42	(530.64)	(108.13)	(1,152.11)
Paid-up Equity share capital (Face value Rs. 10/- per share)	3,526.78	3,526.78	3,526.78	3,526.78
Other Equity (excluding revaluation reserve)				1,238.57
Earnings per equity share				
Basic (in Rs)	0.63	(1.41)	(0.51)	(3.31)
Diluted (in Rs)	0.63	(1.41)	(0.51)	(3.31)



PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Consolidated Financial Results for the Quarter ended 30th June, 2026


Notes to Accounts:

1. The Consolidated Financial Results of Pharmaids Pharmaceuticals Limited (The Holding Company) and its subsidiaries (together referred to as Group) have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules thereafter and in accordance with the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. The Consolidated Financial Results for the quarter ended 30th June 2026 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Holding Company at their respective Meetings held on Aug 12, 2026
4. The group operates in a single segment of providing Contract Research and Manufacturing Services.
5. The figures for the previous periods have been regrouped / reclassified wherever considered necessary.

Place: Bengaluru

Date: 12-08-2026

**By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited**


Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699

